{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Feldstein LR"],"funding":["NIAID NIH HHS"],"pagination":["408-416"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10848053"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["331(5)"],"pubmed_abstract":["<h4>Importance</h4>Bivalent mRNA COVID-19 vaccines were recommended in the US for children and adolescents aged 12 years or older on September 1, 2022, and for children aged 5 to 11 years on October 12, 2022; however, data demonstrating the effectiveness of bivalent COVID-19 vaccines are limited.<h4>Objective</h4>To assess the effectiveness of bivalent COVID-19 vaccines against SARS-CoV-2 infection and symptomatic COVID-19 among children and adolescents.<h4>Design, setting, and participants</h4>Data for the period September 4, 2022, to January 31, 2023, were combined from 3 prospective US cohort studies (6 sites total) and used to estimate COVID-19 vaccine effectiveness among children and adolescents aged 5 to 17 years. A total of 2959 participants completed periodic surveys (demographics,"],"journal":["JAMA"],"pubmed_title":["Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing SARS-CoV-2 Infection in Children and Adolescents Aged 5 to 17 Years."],"pmcid":["PMC10848053"],"funding_grant_id":["75N93021C00015"],"pubmed_authors":["Yoon SK","Ruffin J","Grant L","Hegmann KT","Steinhardt L","Feldstein LR","Naleway AL","Martin ET","Gaglani M","Rai RP","Monto AS","Olsho LEW","Britton A","Babu TM","Vandermeer M","Odame-Bamfo L","Chu HY","Burgess JL","Newes-Adeyi G","Briggs Hagen M","Englund JA","Caban-Martinez AJ","Meece J","Jeddy Z","Smith N","Saydah S","Wiegand R","Lauring AS","Vaughan M","Lutrick K","Midgley CM","Phillips AL","Ellingson KD","Tyner H","Mathenge C"],"additional_accession":[]},"is_claimable":false,"name":"Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing SARS-CoV-2 Infection in Children and Adolescents Aged 5 to 17 Years.","description":"<h4>Importance</h4>Bivalent mRNA COVID-19 vaccines were recommended in the US for children and adolescents aged 12 years or older on September 1, 2022, and for children aged 5 to 11 years on October 12, 2022; however, data demonstrating the effectiveness of bivalent COVID-19 vaccines are limited.<h4>Objective</h4>To assess the effectiveness of bivalent COVID-19 vaccines against SARS-CoV-2 infection and symptomatic COVID-19 among children and adolescents.<h4>Design, setting, and participants</h4>Data for the period September 4, 2022, to January 31, 2023, were combined from 3 prospective US cohort studies (6 sites total) and used to estimate COVID-19 vaccine effectiveness among children and adolescents aged 5 to 17 years. A total of 2959 participants completed periodic surveys (demographics,","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Feb","modification":"2025-04-04T03:24:43.234Z","creation":"2025-04-04T03:24:43.234Z"},"accession":"S-EPMC10848053","cross_references":{"pubmed":["38319331"],"doi":["10.1001/jama.2023.27022"]}}